↓ Skip to main content

Plecanatide: First Global Approval

Overview of attention for article published in Drugs, March 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
2 Mendeley
Title
Plecanatide: First Global Approval
Published in
Drugs, March 2017
DOI 10.1007/s40265-017-0718-0
Pubmed ID
Authors

Zaina T. Al-Salama, Yahiya Y. Syed

Abstract

Plecanatide (Trulance(TM)) is an oral guanylate cyclase-C agonist that is being developed by Synergy Pharmaceuticals for the treatment of gastrointestinal disorders, such as chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It is a synthetic analogue of human uroguanylin, a 16 amino acid peptide that regulates ion and fluid transport in the gastrointestinal tract. In January 2017, plecanatide received its first global approval in the USA for the treatment of adult patients with CIC. Plecanatide is undergoing phase III investigation in IBS-C. This article summarizes the milestones in the development of plecanatide leading to this first approval in CIC.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 2 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 2 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 1 50%
Other 1 50%
Readers by discipline Count As %
Agricultural and Biological Sciences 1 50%
Medicine and Dentistry 1 50%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 July 2017.
All research outputs
#2,935,340
of 11,472,317 outputs
Outputs from Drugs
#542
of 2,328 outputs
Outputs of similar age
#84,498
of 266,938 outputs
Outputs of similar age from Drugs
#13
of 36 outputs
Altmetric has tracked 11,472,317 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 2,328 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,938 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.